NEW YORK (GenomeWeb News) – Molecular diagnostic firm Linkage Biosciences today announced it raised $2 million in growth capital.

The company did not specify how the funds will be used, but CEO Zachary Antovich noted growing demand for the firm's LinkSeq products and said in a statement that the funds will "help accelerate our efforts around the world."

Fisher Capital led the round. All existing investors, including Greenhouse Capital Partners and Big Sky Partners, also participated, Linkage Bio said

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.